IPHA

Innate Pharma Announces Conference Call and Webcast for Q1 2022 Business Update

Retrieved on: 
화요일, 5월 3, 2022
Biotechnology, Health, Oncology, Clinical Trials, Antibody, EDT, Immune system, Novo Nordisk, Telephone, Company, Tumor microenvironment, Patient, Webcast, Euronext Paris, Cancer, CEST, IPH, Investor, Sanofi, IPHA, AstraZeneca, Bristol Myers Squibb, Vaccine, Fine chemical, Nasdaq, MD

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company), today announced that the Company will hold a conference call on Tuesday, May 10, 2022 at 2 p.m. CEST / 8 a.m. EDT, to give an update on business progress during the first quarter of 2022.

Key Points: 
  • Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company), today announced that the Company will hold a conference call on Tuesday, May 10, 2022 at 2 p.m. CEST / 8 a.m. EDT, to give an update on business progress during the first quarter of 2022.
  • Speakers during the call will be:
    The live webcast will be available at the following link:
    Participants may also join via telephone using the dial-in details below:
    This information can also be found on the Investors section of the Innate Pharma website, www.innate-pharma.com .
  • A replay of the webcast will be available on the Company website for 90 days following the event.
  • Headquartered in Marseille, France, with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.

Innate Pharma: First Patient Dosed in Monalizumab Phase 3 Lung Cancer Clinical Trial Triggers $50M Payment From AstraZeneca

Retrieved on: 
금요일, 4월 29, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Cancer, NK, Antibody, Novo Nordisk, Safety, Immune system, Euronext Paris, Progression-free survival, PD-L1, PFS, Patient, Oncology, Journal, European Society for Medical Oncology, Lymphatic system, Neoplasm, NSCLC, Lung cancer, ESMO, IPH, ORR, American Journal of Clinical Oncology, Bristol Myers Squibb, Oleclumab, AstraZeneca, IPHA, CRT, Squamous cell carcinoma, Tumor microenvironment, Congress, IIIC, Survival, Sanofi, Pharmaceutical industry, Vaccine, Monalizumab, Durvalumab, Nasdaq, MD, Intrinsic and extrinsic properties

Dosing of the first patient in this trial has triggered a $50 million milestone payment from AstraZeneca to Innate.

Key Points: 
  • Dosing of the first patient in this trial has triggered a $50 million milestone payment from AstraZeneca to Innate.
  • We are very pleased that our key late-stage asset, monalizumab, has progressed into a second Phase 3 trial with our partner, AstraZeneca.
  • Detailed results from the randomized COAST Phase 2 trial were published in the Journal of Clinical Oncology on April 22, 2022.
  • Including the $50 million payment triggered by dosing the first patient in the Phase 3 PACIFIC-9 clinical trial, Innate Pharma has received $450 million to date.

Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 20, 2022

Retrieved on: 
금요일, 4월 8, 2022
Biotechnology, Health, Oncology, Cancer, IPH, Code, Euronext Paris, Novo Nordisk, Tumor microenvironment, CEST, Bristol Myers Squibb, AstraZeneca, Immune system, Documentation, Annual, IPHA, Sanofi, Patient, AGM, Antibody, Fine chemical, Security (finance), Vaccine, MD, Nasdaq

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) will hold its Annual General Meeting of Shareholders (AGM) at 10:30 a.m. CEST on May 20, 2022 in its headquarters, 117 avenue de Luminy, F-13009 Marseille.

Key Points: 
  • Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) will hold its Annual General Meeting of Shareholders (AGM) at 10:30 a.m. CEST on May 20, 2022 in its headquarters, 117 avenue de Luminy, F-13009 Marseille.
  • The Notice of Meeting of this AGM was published on April 8, 2022 in the French legal bulletin.
  • It includes the agenda, the proposed resolutions as well as instructions to participate and vote in this AGM.
  • Headquartered in Marseille, France, with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.

Innate Pharma Announces Conference Call and Webcast for Full Year 2021 Financial Results

Retrieved on: 
목요일, 3월 17, 2022
Biotechnology, Pharmaceutical, Health, Oncology, Bristol Myers Squibb, Patient, Euronext Paris, Tumor microenvironment, IPHA, Novo Nordisk, AstraZeneca, Antibody, CET, IPH, Company, Cancer, Telephone, Webcast, Immune system, Investor, Sanofi, Vaccine, Fine chemical, MD, Nasdaq

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company), today announced that the Company will hold a conference call on Thursday, March 24, 2022 at 2 p.m. CET / 9 a.m.

Key Points: 
  • Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company), today announced that the Company will hold a conference call on Thursday, March 24, 2022 at 2 p.m. CET / 9 a.m.
  • ET, following the release of its financial results for the full year ending December 31, 2021.
  • A replay of the webcast will be available on the Company website for 90 days following the event.
  • Headquartered in Marseille, France, with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.

Innate Pharma: First Patient Dosed in IPH6101/SAR443579 Phase 1/2 Clinical Trial in Various Blood Cancers

Retrieved on: 
목요일, 12월 16, 2021
Biotechnology, Pharmaceutical, Health, Oncology, Therapy, Society, Immunotherapy, NK, AML, Company, Novo Nordisk, Acute lymphoblastic leukemia, FACP, Master of Science, Clinical trial, Cancer, Euronext Paris, Tumor microenvironment, SITC, AstraZeneca, IPHA, Pharmacokinetics, Research, Safety, Patient, Immune system, B-ALL, Tetra, IPH, CD16, Society for Immunotherapy of Cancer, Acute myeloid leukemia, Bristol Myers Squibb, Congress, Antibody, Technology, Pharmaceutical industry, Generic drug, Vaccine, Intrinsic and extrinsic properties, Nasdaq, Sanofi, MD, NCR1, ANKETTM, IPH6101/SAR443579, the Innate-Sanofi agreement, Innate Pharma, ANKETTM, IPH6101/SAR443579, THE INNATE-SANOFI AGREEMENT, INNATE PHARMA

Were pleased with the initiation of the clinical trial for IPH6101/SAR443579, which is the first ANKETTM asset to enter the clinic.

Key Points: 
  • Were pleased with the initiation of the clinical trial for IPH6101/SAR443579, which is the first ANKETTM asset to enter the clinic.
  • The start of the trial has triggered a milestone payment from Sanofi to Innate, which is part of a previously announced research collaboration with Sanofi.
  • Innate Pharmas broad pipeline of antibodies includes several potentially first-in-class clinical and preclinical candidates in cancers with high unmet medical need.
  • Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.

Innate Pharma: Monalizumab Combined With Cetuximab and Durvalumab Demonstrates Anti-Tumor Activity in First-Line Recurrent or Metastatic Head and Neck Cancer at ESMO Immuno-Oncology 2021 Congress

Retrieved on: 
목요일, 12월 9, 2021
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Master of Science, FACP, ESMO, CPS, NK, Patient, Antibody, Euronext Paris, Survival rate, IPHA, IPH, Survival, AstraZeneca, Cetuximab, Pharmaceutical industry, Monalizumab, Innate Pharma, MONALIZUMAB, INNATE PHARMA

These data show anti-tumor activity in the first study to evaluate this chemo-free triplet combination in first-line recurrent or metastatic head and neck cancer, said Joyson Karakunnel, M.D., MSc, FACP, Chief Medical Officer of Innate Pharma.

Key Points: 
  • These data show anti-tumor activity in the first study to evaluate this chemo-free triplet combination in first-line recurrent or metastatic head and neck cancer, said Joyson Karakunnel, M.D., MSc, FACP, Chief Medical Officer of Innate Pharma.
  • We believe that the combination of monalizumab with the other two antibodies has the potential to become a new treatment option for patients.
  • After a median follow-up of 16.3 months, preliminary data suggest anti-tumor activity in the triplet of monalizumab, cetuximab and durvalumab in first-line treatment of R/M HNSCC.
  • Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.

Innate Pharma to Present Monalizumab Data at ESMO Immuno-Oncology 2021 Congress

Retrieved on: 
목요일, 12월 2, 2021
Biotechnology, Pharmaceutical, Health, Oncology, Patient, Euronext Paris, Cancer, Cetuximab, Technology, NCR1, Head, Novo Nordisk, Bristol Myers Squibb, IPH, Tumor microenvironment, NK, IPHA, AstraZeneca, DVM, Neck, CET, ESMO, IO, CD16, Antibody, Sanofi, Immune system, Therapy, Lymphatic system, Pharmaceutical industry, Vaccine, Monalizumab, ANKETTM, Innate Pharma, MONALIZUMAB, ANKETTM, INNATE PHARMA

Eric Vivier, Ph.D., DVM, Chief Scientific Officer at Innate Pharma, will present in the NK cell biology educational session.

Key Points: 
  • Eric Vivier, Ph.D., DVM, Chief Scientific Officer at Innate Pharma, will present in the NK cell biology educational session.
  • Monalizumab is a potentially first-in-class immune checkpoint inhibitor targeting NKG2A receptors expressed on tumor-infiltrating cytotoxic CD8+ T cells and NK cells.
  • The ongoing development for monalizumab is focused on investigating monalizumab in various combination strategies in different malignancies.
  • Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.

Innate Pharma Third Quarter 2021 Report

Retrieved on: 
화요일, 11월 16, 2021
Biotechnology, Pharmaceutical, Health, Oncology, AML, Oxaliplatin, Progression-free survival, Cancer, European Society for Medical Oncology, Congress, CD16, ESMO, Tumor microenvironment, Bristol Myers Squibb, Webcast, Oncology, Cell, PFS, Institute, NCR1, Neck, Acute myeloid leukemia, Euronext Paris, Telephone, Â, CET, Cetuximab, Novo Nordisk, Patient, Natural killer T cell, Investor, Oleclumab, Society, GEMOX, IO, Metastasis, NSCLC, ORR, Immunotherapy, COAST, Head, AstraZeneca, SITC, Tetra, Immune system, CD123, NK, PTCL, IPHA, Society for Immunotherapy of Cancer, Neoplasm, Company, Antibody, ADCC, IPH, Fine chemical, Pharmaceutical industry, Vaccine

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today announced its revenues and cash position for the first nine months of 2021.

Key Points: 
  • Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today announced its revenues and cash position for the first nine months of 2021.
  • ET)
    The live webcast will be available at the following link:
    Participants may also join via telephone using the following dial in numbers:
    This information can also be found on the Investors section of the Innate Pharma website, www.innate-pharma.com .
  • In September and November 2021, Innate also presented at the ESMO 2021 and SITC conferences respectively.
  • Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.

Momentum Grows for Morreale Healthcare Practice with International Award Recognition

Retrieved on: 
수요일, 10월 20, 2021
Woman, Program, LGBTQ, WBE, Research, Homelessness, Stevie Awards, Workplace, Diversity, Organization, Sports broadcasting contracts in Middle East & North Africa, Policy, Achievement, Gold, Disability, COVID-19, Multimedia, IPHA, Solution, Female, Customer service, Community, Minister of Immigration, Refugees and Citizenship, Medicine, Tourism, Film

This represents the highest honor achievable for the Stevie Awards and is the firms 20th award in it's 15-years history.

Key Points: 
  • This represents the highest honor achievable for the Stevie Awards and is the firms 20th award in it's 15-years history.
  • "Morreale is honored to be recognized with Gold Stevie Awardsfor our results-oriented work that continues to provide diverse communities across our state with trusted sources of information," said Kim Morreale, President/CEO of Morreale Communications.
  • Morreale demonstrated the experience and relationships necessary to strengthen our program in the state's COVID-19 effort and surpassed all expectations," said Tom Hughes, IPHA.
  • Morreale Communications is a leading strategic communications agency working at the intersection of business, media, policy and people.

Monalizumab Data from COAST Trial Presented at ESMO Congress 2021

Retrieved on: 
금요일, 9월 17, 2021
Squamous cell carcinoma, Cancer, Bristol Myers Squibb, European Society for Medical Oncology, Oleclumab, Immune system, Novo Nordisk, Antibody, Durvalumab, Cell biology, Sanofi, Patient, ESMO, IPHA, Natural killer T cell, Oncology, Safety, ORR, IIIC, CRT, IPH, Progression-free survival, Neoplasm, Tumor microenvironment, NSCLC, Lymphatic system, Lung cancer, GLOBE, Intrinsic and extrinsic properties, AstraZeneca, Euronext Paris, PFS, Congress, Vaccine, Pharmaceutical industry

MARSEILLE, France, Sept. 17, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today announced that AstraZeneca (LSE/STO/Nasdaq: AZN) presented results from the randomized COAST Phase 2 trial during the European Society for Medical Oncology (ESMO) Congress 2021 on September 17, 2021.

Key Points: 
  • MARSEILLE, France, Sept. 17, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today announced that AstraZeneca (LSE/STO/Nasdaq: AZN) presented results from the randomized COAST Phase 2 trial during the European Society for Medical Oncology (ESMO) Congress 2021 on September 17, 2021.
  • To read more about the Phase 2 COAST results, please see AstraZenecas press release here .
  • Were pleased to see the monalizumab COAST results, particularly the improved clinical outcomes for patients with unresectable, Stage III non-small cell lung cancer, said Mondher Mahjoubi, Chief Executive Officer of Innate Pharma.
  • The ongoing development for monalizumab is focused on investigating monalizumab in various combination strategies in different malignancies.